REGISTERED NUMBER: 11826246 (England and Wales)

PERENNIAL PHARMA LTD

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 JULY 2025

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

4

DIRECTOR:

J L Durbidge

REGISTERED OFFICE:

2nd Floor

Titan Court

3 Bishop Square

Hatfield

Hertfordshire

AL10 9NA

REGISTERED NUMBER:

11826246 (England and Wales)

ACCOUNTANTS:

Spurling Cannon

King Arthur's Court

Maidstone Road

Charing

Kent

TN27 0JS

FIXED ASSETS

Intangible assets

4

714,866

354,564

Tangible assets

5

525

618

Investments

6

67,500

-

782,891

355,182

CURRENT ASSETS

Stocks

1,064,967

360,824

Debtors

7

1,799,541

1,761,035

Cash at bank and in hand

95,824

349,740

2,960,332

2,471,599

CREDITORS

Amounts falling due within one year

8

3,019,356

2,152,602

NET CURRENT (LIABILITIES)/ASSETS

(59,024

)

318,997

TOTAL ASSETS LESS CURRENT LIABILITIES

723,867

674,179

CAPITAL AND RESERVES

Called up share capital

9

1,099

100,000

Retained earnings

722,768

574,179

SHAREHOLDERS' FUNDS

723,867

674,179

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 July 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 July 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 10 February 2026 and were signed by:

J L Durbidge - Director

1.	STATUTORY INFORMATION

Perennial Pharma Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of nil years.

Computer software is being amortised evenly over its estimated useful life of nil years.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery etc

-

Straight line over 3 years

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 5 (2024 - 4 ) .

4.	INTANGIBLE FIXED ASSETS

Patents

and

Computer

licences

software

Totals

£

£

£

COST OR VALUATION

At 1 August 2024

375,956

19,362

395,318

Additions

275,073

-

275,073

Revaluations

206,000

-

206,000

At 31 July 2025

857,029

19,362

876,391

AMORTISATION

At 1 August 2024

29,137

11,617

40,754

Amortisation for year

116,898

3,873

120,771

At 31 July 2025

146,035

15,490

161,525

NET BOOK VALUE

At 31 July 2025

710,994

3,872

714,866

At 31 July 2024

346,819

7,745

354,564

Cost or valuation at 31 July 2025 is represented by:

Patents

and

Computer

licences

software

Totals

£

£

£

Valuation in 2023

209,000

-

209,000

Valuation in 2024

166,956

19,362

186,318

Valuation in 2025

481,073

-

481,073

857,029

19,362

876,391

5.	TANGIBLE FIXED ASSETS

Fixture &

Computer

Fittings

equipment

Totals

£

£

£

COST

At 1 August 2024

and 31 July 2025

1,318

1,587

2,905

DEPRECIATION

At 1 August 2024

700

1,587

2,287

Charge for year

93

-

93

At 31 July 2025

793

1,587

2,380

NET BOOK VALUE

At 31 July 2025

525

-

525

At 31 July 2024

618

-

618

6.	FIXED ASSET INVESTMENTS

Loans to

associates

£

New in year

67,500

At 31 July 2025

67,500

7.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2025

2024

£

£

Trade debtors

1,798,542

1,661,135

Called up share capital not paid

999

99,900

1,799,541

1,761,035

8.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2025

2024

£

£

Bank loans and overdrafts

960,000

660,000

Trade creditors

1,763,616

1,319,051

Corporation Tax

92,473

71,022

VAT

193,235

83,422

Directors' current accounts

520

9,595

Accrued expenses

9,512

9,512

3,019,356

2,152,602

9.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

2025

2024

value:

£

£

100

Ordinary

1

100

100,000

99,900

Ordinary A

.01

999

-

1,099

100,000